With the support of the Development Fund of Georgia, an ultra-modern radiopharmaceutical facility will be built in Georgia

With financial support from the Development Fund of Georgia, the Georgian company Novatech International will build Georgia’s first state-of-the-art, high-tech radiopharmaceutical plant, enabling the local production of a radioactive isotope using a cyclotron accelerator.

The radioactive isotope is used in advanced technology such as positron emission tomography/computed tomography (PET-CT), which, compared with other tomographic examinations, can detect tumours even before any clinical signs appear. It also enables benign and malignant tumours to be differentiated with high accuracy, supporting the early diagnosis and appropriate treatment of a range of diseases.

“As you know, the radioactive isotope is currently imported entirely from abroad. Launching this type of production in Georgia is therefore an unprecedented development and a major step forward for the medical sector,” said Besik Bugianishvili, Executive Director of the Development Fund of Georgia.

High-tech manufacturing, including biotechnology and medical technology, is one of the priorities of the reformed Development Fund of Georgia. The Fund aims to ensure that growth in local production gradually reduces and replaces imports.

The project’s investment value is EUR 9 million, of which the Development Fund of Georgia is contributing EUR 1.8 million. Construction of the plant near Tbilisi is currently in an active phase, in accordance with the requirements of the International Atomic Energy Agency (IAEA), the manufacturer’s recommendations and international standards. Operations are scheduled to begin by 2026. Production processes will also fully comply with EU GMP (Good Manufacturing Practice) requirements.